Optimized Neoantigen Synthetic Long Peptide Vaccine
Gastroesophageal Adenocarcinoma
Explore 40 assets in Gastroesophageal Adenocarcinoma →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Washington University School of Medicine
Modality
vaccine
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06529822CT.gov Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastroesophageal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Optimized Neoantigen Synthetic Long Peptide Vaccine (this asset) | Washington University School of Medicine | P1 | C · 39 |
| Oxaliplatin | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Pembrolizumab | Diwakar Davar | P3 | BB |
| Nivolumab | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Trastuzumab | UNICANCER | P3 | BB |
| Lenvatinib | Merck Sharp & Dohme LLC | P3 | B |
| Capecitabine | Shanghai Zhongshan Hospital | P3 | B |
| Fluorouracilum | Memorial Sloan Kettering Cancer Center | P3 | B |
| Zanidatamab | Tao Zhang | P3 | B |
+42 more in the Gastroesophageal Adenocarcinoma cohort
Other indications for Optimized Neoantigen Synthetic Long Peptide Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infiltrating Bladder Urothelial Carcinoma | — | P1 | CC · 43 |
| Malignant Pancreatic Neoplasm | — | P1 | CC · 42 |
| Pancreatic Neoplasm | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Optimized Neoantigen Synthetic Long Peptide Vaccine in Gastroesophageal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/optimized-neoantigen-synthetic-long-peptide-vaccine-gastroesophageal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →